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Infl uence of photon beam energy on IMRT 
plan quality for radiotherapy of prostate 
cancer
Gopi SOLAIAPPAN1, Ganesan SINGARAVELU2, Aruna PRAKASARAO3, 
Bouchaib RABBANI4, Sanjay S. SUPE5
SUMMARY
BACKGROUND: Intensity-modulated radiation therapy (IMRT) has been widely used for prostate can-
cer treatments. 6MV photon beams were found to be an effective energy choice for most IMRT cases. 
The use of high-energy photons raise concerns about increased leakage and secondary neutron dose 
for the patients. 
AIM: In this work, the effect of beam energy on the quality of IMRT plans for prostate radiotherapy 
was systematically studied for competing IMRT plans optimized for delivery with either 6 or 10MV 
beams. 
MATERIALS AND METHODS: A cohort of 20 prostate cases was selected for this study. All patients 
received full-course IMRT treatments to a dose of 79.2Gy to PTV in 44 fractions. For all of the cases 
we developed treatment plans using 6 MV and 10MV intensity-modulated beams with identical dose 
volume constraints. 
RESULTS: Percentage of doses received by the percentage volume of PTV was higher for 6MV photons 
compared to 10MV photons for 12 patients, less than or equal to 1% for 6 patients and 2.6%, 3.6% for 
the remaining 2 patients irrespective of the PTV volume. Percentage doses received by 15% of bladder 
volume were higher for 10 MV photons. Percentage doses received by 15% of rectum volume were 
also higher for 10 MV photons. 
CONCLUSIONS: Since there is no greater advantage from 10MV photons as compared with 6MV pho-
tons in large volume pelvic IMRT dosimetry and also 10MV photons lie on the threshold energy border 
for the induction of photo neutrons from the accelerator components, we recommend the use of 6MV 
photons for IMRT of prostate cancer to achieve better results in tumour control and acceptable prob-
ability of complication rate.
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BACKGROUND
A standard principle in radiation therapy has 
been that the deeper the target, the higher the 
energy that should be used. As is known from 
the literature, energies ≥ 10 MV are to be pre-
ferred for deep-seated pelvic/abdominal le-
sions, particularly for larger target volumes 
or larger size patients [1], due to a decrease 
in the integral dose. In addition, it has been 
shown that dose deposition near and distant 
from the target is different for different en-
ergies. Low energy produces tighter dose dis-
tributions around the target than higher en-
ergies, but also deposits a higher dose in the 
surface region near the beam entry [1, 2].
In contrast, one of the implied tenets of in-
tensity-modulated radiation therapy (IMRT) 
has been that energy does not matter [3] or is 
less important [4]. This thesis was originally 
examined and shown to be the case for rota-
tional IMRT (TomoTherapy), based on the 
equivalence of mean dose to target and sen-
sitive structures at different energies [3]. In 
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fact, although it has been suggested by Soder-
strom et al. that there is still a value to higher 
energies for deep seated targets as the volume 
of the target increases [4], the results on rota-
tional delivery have been used by accelerator 
manufacturers to guide the development of 
IMRT-dedicated single energy machines us-
ing 6 or 10 MV photon beam energies.
Intensity-modulated radiation therapy 
(IMRT) has been widely used for prostate 
cancer treatment [5–19]. In practice, high-
energy photons such as 18 MV are often used, 
given the experience of 3D conformal radia-
tion therapy with static beams. However, in 
IMRT treatments, the effects of the intensity 
modulation and the use of a relatively large 
number of beams have been found to reduce 
the dependence of the treatment planning on 
the selection of beam energies [20]. As a re-
sult, 6-MV photon beams have been found to 
be an effective energy choice for most IMRT 
cases [4,21].
In addition, the total monitor units are typi-
cally two to three times higher in IMRT than 
in conventional radiation therapy. Therefore, 
the use of high-energy photons also raised 
concerns about increased leakage and sec-
ondary neutron dose for the patients [22-24]. 
However, it is unclear whether low-energy 
intensity-modulated photons can be used for 
large-pelvis irradiations because of the low 
penetration power of the beam.
AIM
In this work, the effect of beam energy on the 
quality of IMRT plans for prostate radiother-
apy was systematically studied for compet-
ing IMRT plans optimized for delivery with 
either 6 or 10 MV beams. To ensure that dif-
ferences among plans are due only to energy 
selection, the beam arrangement, number of 
beams, and dose constraints were kept con-
stant for all plans.
MATERIALS AND METHODS
A cohort of 20 prostate cases was selected 
for our study. The patient characteristics are 
given in Table I. The mean anterior-posterior 
(AP) separation of these patients was 23.3 cm 
(range 18–30 cm, SD 3.1) and the mean lateral 
separation was 37.7 cm (range 34–40 cm, SD 
2.00). The prostate volume varied from 16.8 
to 181.9 cc (mean 69.2 cc, SD 41.4). The plan-
ning target volume (PTV) was defi ned as the 
entire prostate without seminal vesicles and 
included a 3 mm margin around the prostate 
for set-up error. The average PTV for these 
patients was 123.7 cc (range 38.9–270.9 cc, 
SD 57.5 ). The rectum and bladder volumes 
varied from 34.2 to 267.2 cc and 89.9 to 441.9 
cc respectively (mean 89.7, SD 49.2 and mean 
228.3, SD 114.7).
All patients received full-course IMRT 
treatments to a dose of 79.2 Gy to PTV in 
44 fractions. For inverse IMRT treatment 
planning, we used a 6-coplanar non-opposed 
beam arrangement at 225, 270, 0, 75, 105 and 
135 degree angles. Fields were selected so 
that all entrance and exit beams were spaced 
about the patient. The plan was generated 
on a commercial Corvos treatment planning 
system (Nomos Radiation Oncology, a divi-
sion of North American Scientifi c, PA, USA). 
For all plans we defi ned dose volume con-
straints as given in Table 2. Deliveries were 
modelled using actual beam data for delivery 
with a Clinac-iX linear accelerator using a 
millennium 120 multileaf collimator in dy-
namic mode (Varian Medical Systems, Palo 
Alto, CA, USA). For all of the cases we devel-
oped treatment plans using 6 MV and 10 MV 
intensity-modulated beams with identical 
dose volume constraints. The dose volume 
histograms (DVHs) for the 6-MV and 10-MV 
plans were compared for PTV and for criti-
cal structures such as the rectum, bladder, 
femoral heads, small intestine and urethra. 
We also defi ned the conformal index to com-
pare the treatment plans. The conformal in-
dex was defi ned as the ratio of the 95% isod-
ose volume divided by the PTV volume that is 
enclosed by the 95% isodose line, since we se-
lected the 95% isodose line as our reference. 
From this defi nition the closer the conformal 
index approaches 1.0, the more conformal is 
the treatment plan. We also calculated the 
integral dose surrounding normal tissue by 
integrating the dose over all voxels within 
the volume. 
RESULTS
The dose distributions for a sample patient 
along axial, coronal and sagittal planes are 
shown in Fig. 1 and 2 for 6 MV and 10 MV 
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photon beams respectively. The dose volume 
histograms for PTV and various critical nor-
mal structures are shown in Fig. 3 for both 6 
MV and 10 MV photon beams.
The PTV dosimetry details regarding doses 
received by 98%, 95% and 92% of PTV are giv-
en in Table III. Differences in doses received 
by 95% of PTV for the 10 MV photon beam 
Patient 
number
AP
(cm)
Lat
(cm)
Prostate Volume 
(cc)
PTV Volume 
(cc)
Rectum Volume 
(cc)
Bladder Volume 
(cc)
1 25 37 16.8 38.9 34.2 89.9
2 20 34 30.9 70.8 38.1 99.2
3 22 36 33.2 68.6 47.4 99.9
4 25 40 34.8 64.9 61.0 110.4
5 21 38 36.5 79.3 61.3 112.2
6 20 36 40.1 89.7 69.9 119.0
7 23 36 40.5 89.9 70.3 125.1
8 18 34 47.6 88.4 71.1 127.4
9 21 35 48.9 90.6 71.4 161.1
10 23 38 50.9 99.0 71.9 170.6
11 22 39 57.3 104.8 77.7 223.5
12 22 38 62.8 112.9 78.4 241.0 
13 28 39 63.6 132.0 79.8 252.6
14 24 40 64.8 113.8 81.0 261.2
15 26 40 68.2 133.0 86.7 323.6 
16 21 38 80.7 135.7 95.2 333.6 
17 27 38 105.8 178.5 121.3 374.2 
18 30 40 121.2 190.9 124.5 380.1 
19 27 39 145.3 237.1 129.3 381.9 
20 22 39 181.9 270.9 267.2 441.9
Table 1. Patient characteristics for the cohort
Structure Goal (Gy)
Volume below goal 
in %
Minimum
(Gy)
Maximum
(Gy)
Prostate target 79.2 5 76 83
Seminal vesicles target 65.0 5 62 79
Structure Goal (Gy) Volume above limit in %
Minimum
(Gy)
Maximum
(Gy)
Tissue 76 0 0 79
Bladder 50 25 1 65
Femoral heads 40 10 1 50
Rectum 50 20 1 65
Small intestine 30 5 1 35
Urethra 35 5 1 40
Table 2. The optimization constraints used for all IMRT plans
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versus the 6 MV photon beam are indicated in 
Table IV. Fig. 4 shows the percentage dose of 
prescription dose received by each patient for 
98%, 95% and 92% of PTV. Bladder dosimetry 
data regarding mean dose to bladder, volume 
in cc receiving >65 Gy and volume in percent-
age receiving >65 Gy are given in Table V. 
Bladder doses in Gy and percentage for 17% 
and 15% of volumes are given in Table VI. Fig 
5. shows the % volume receiving >65 Gy, and 
percentage dose received by 15 and 17% vol-
ume.
Rectum dosimetry data regarding mean 
dose to rectum, volume in cc receiving >65 
Gy and volume in percentage receiving >65 
Gy are given in Table VII. Rectum doses in Gy 
and percentage for 17% and 15% of volumes 
are given in Table VIII. Fig 6. shows the % 
volume receiving >65 Gy, percentage dose re-
ceived by 17% volume and percentage dose re-
Fig. 1. Dose distribution along axial, coronal and sagittal 
planes for 6 MV photon beam
Fig. 2. Dose distribution along axial, coronal and sagittal 
planes for 10 MV photon beam
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ceived by 15% volume. Normal tissue integral 
doses for the twenty patients included in this 
study for 6 MV and 10 MV photon beams are 
depicted in Table IX. Conformity index values 
for these patients are given in Table X. 
DISCUSSION 
Pirzkall et al. [20] examined the infl uence 
of energy and number of beams on nontar-
get dose when using intensity-modulated ra-
diation therapy (IMRT) to treat deep-seated 
targets. Ten patients with prostate cancer 
(36–226 cc) treated locally to 75.6 Gy were 
studied. IMRT plans were created for 6-, 
10-, and 18-MV photons using 4, 6, 9, and 11 
coplanar nonopposed fi elds. Plans, normal-
ized to cover 95% of the target volume, were 
analyzed using: (a) conformity index (CI) 
at 105%, 100%, 95%, 90%, 80%, 70%, 50% of 
Fig. 3. Dose volume histograms for 6MV and 10 MV photon 
beams
Fig. 5. Bladder dosimetry data
Fig. 6. Rectum dosimetry data
Fig. 4. Precentage dose of prescription dose received by 
each patient
prescribed dose; (b) prescription isodose line 
(PI); (c) minimum dose to target (Tarmin); 
(d) maximum dose to tissue (Tismax); (e) 
dose to rectum/bladder/penis bulb; (f) inte-
gral nontarget dose (ID). Because CI evalu-
ates dose independently of location, tissue 
was also divided into “near region” (NR: 
1-cm thick shell surrounding target) and “far 
region” (FR: tissue minus NR) volumes that 
were evaluated at the same levels as CI. Re-
sults: The target and sensitive structure met-
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rics were the same for all plans. However, 
although there was little difference in NR 
volume exposed to dose, regardless of energy 
or number of fi elds, there was a signifi cant 
increase in FR volume exposed to dose, at 
all levels, for low energy/few fi eld plans com-
pared to high energy/many fi elds (e.g., > 50 
cc > 65 Gy). This effect disappeared with > 
9 fi elds regardless of energy. With IMRT, the 
use of 6 MV photons with less than 9 fi elds 
may result in an increase in dose in regions 
distant from the target volume (e.g., near the 
skin surface), even though the CI and sensi-
tive structure metrics may indicate good con-
formance of high dose to the target volume 
itself. The clinical signifi cance of this in-
creased dose distant from the target, in terms 
of complications, remains to be determined.
An inverse planning technique using 6-MV 
intensity-modulated photon beams was devel-
oped by Sun and Ma [25] for treating large-
size patients with prostate cancer. Com-
parisons of treatment plans using 6-MV and 
18-MV intensity-modulated beams were car-
ried out for a cohort of 10 patient cases. For 
these cases, they analyzed the dependence of 
plan quality on the beam energies and found 
that 6-MV beams resulted in plans equivalent 
to those for 18-MV beams both for targets and 
for critical structures such as the rectum and 
bladder. The differences between the plans 
in the integral dose and the mean dose to the 
normal tissue surrounding the target were 
found to be small, in contrast to those for 3D 
conformal plans. Our fi ndings showed that the 
low entrance dose of the high-energy photon 
beams is mostly compensated by the high exit 
dose for even exceptionally large patients. In 
conclusion, 6-MV intensity-modulated beams 
are a feasible choice for treating large-size 
Patient Number PTV 
Volume 
(cc)
Dose (Gy) received by % of PTV
98% PTV 95% PTV 92% PTV
6 MV 10 MV 6 MV 10 MV 6 MV 10 MV
1 38.91 71.32 67.08 72.45 68.90 73.52 70.01
2 70.81 72.31 72.48 72.86 73.55 72.86 74.00
3 68.63 73.10 72.89 73.74 73.67 74.13 74.14
4 64.85 71.11 71.41 72.10 72.48 72.63 73.11
5 79.29 73.38 72.48 73.89 73.00 74.19 73.31
6 89.70 72.17 72.63 72.97 73.41 73.37 73.76
7 89.95 72.82 70.88 73.79 71.45 74.19 71.72
8 88.37 70.58 72.44 71.17 73.22 71.49 73.69
9 90.56 72.56 69.97 73.31 71.03 73.62 71.65
10 99.01 72.16 71.32 72.84 71.94 73.16 72.31
11 104.79 71.60 71.83 72.11 72.32 72.44 72.59
12 112.86 71.83 70.78 72.71 72.19 73.20 72.77
13 132.04 71.66 68.28 72.33 69.40 72.68 69.97
14 113.84 72.95 73.49 73.62 74.22 74.02 74.57
15 132.99 72.23 71.64 72.78 72.30 73.02 72.72
16 135.66 74.71 73.96 74.44 74.54 74.96 75.23
17 178.50 69.44 72.69 70.61 73.49 71.02 73.89
18 190.91 72.44 70.73 73.00 71.32 73.36 71.64
19 237.10 69.25 68.61 70.33 69.47 70.92 69.89
20 270.91 71.82 70.69 72.52 71.29 72.94 71.63
Table 3. PTV dosimetry details
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patients with prostate cancer, provided that 
proper inverse planning techniques are ad-
opted.
Three dimensional conformal radiation 
therapy (3DCRT) for prostate cancer is most 
commonly delivered with high-energy pho-
tons, typically in the range of 10–21 MV. With 
the advent of intensity-modulated radiation 
therapy (IMRT), an increase in the number of 
monitor units (MU) relative to 3DCRT has led 
to a concern about secondary malignancies. 
This risk becomes more relevant at higher 
photon energies where there is a greater neu-
tron contribution. Subsequently, the majority 
of IMRT prostate treatments being delivered 
today are with 6–10 MV photons where neutron 
production is negligible. However, the absolute 
risk is small [Hall, E. J. Intensity-modulated 
radiation therapy, protons, and the risk of sec-
ond cancers. Int J Radiat Oncol Bio Phys 65, 
1–7 (2006); Kry, F. S., Salehpour, M., Followill, 
D. S., Stovall, M., Kuban, D. A., White, R. A., 
and Rosen, I. I. The calculated risk of fatal 
secondary malignancies from intensity-modu-
lated radiation therapy. Int J Radiat Oncol Bio 
Phys 62, 1195–1203 (2005)] and therefore it has 
been suggested that the use of 18 MV IMRT 
may achieve better target coverage and normal 
tissue sparing such that this benefi t outweighs 
the risks. This study investigated whether 18 
MV IMRT offers better target coverage and 
normal tissue sparing. Computed tomography 
(CT) image sets of ten prostate cancer patients 
were acquired and two separate IMRT plans 
were created for each patient. One plan used 6 
MV beams, and the other used 18 MV, both in a 
coplanar, non-opposed beam geometry. Beam 
arrangements and optimization constraints 
were the same for all plans. Boer et al. [26] in-
cluded a comparison and discussion of the total 
integral dose, neutron dose conformity index, 
and total number of MU for plans generated 
with both energies.
 Weiss et al. [27] analyzed the supposed ben-
efi ts of low over high photon energies for the 
radiotherapy of lung cancer. For 13 patients, 
6- and 18-MV IMRT planning was performed 
using identical planning objectives and dose 
constraints. Plans were compared according 
to dose–volume histogram (DVH) analysis in-
cluding conformity and homogeneity indices 
(CI and HI) and overall plan quality (compos-
ite score CS), considering also magnitude and 
location of planning target volumes (PTVs). 
With 6-MV plans, CSs were better in 11/13, 
HIs in 10/13 and CIs in 6/13 patients com-
pared with 18-MV plans. Six-MV plans result-
ed in better normal tissue sparing except for 
specifi ed dose levels to the thorax and spinal 
cord. On average differences between 6 and 
18 MV both for the PTV and normal tissues 
were not statistically signifi cant (p > 0.05). 
Considering size and location of the PTVs as 
well as their relative position to normal tissue, 
overall no signifi cant differences between 6 
and 18 MV were observed. Conclusions: On 
average no clinically or statistically signifi -
cant differences between 6- and 18-MV plans 
were observed. High photon energies should 
therefore not be excluded a priori when a 
dose-calculation algorithm is utilized that ac-
curately accounts for heterogeneities.
Patient 
number
PTV Volume 
(cc)
Difference in percentage of dose 
received by % of PTV
(10 MV vs 6 MV)
95 % PTV
1 38.9 -4.5
2 70.8 0.9
3 68.6 -0.1
4 64.9 0.5
5 79.3 -1.1
6 89.7 0.6
7 90.0 -3.0
8 88.4 2.6
9 90.6 -2.9
10 99.0 -1.1
11 104.8 0.3
12 112.9 -0.7
13 132.0 -3.7
14 113.8 0.8
15 133.0 -0.6
16 135.7 0.1
17 178.5 3.6
18 190.9 -2.1
19 237.1 -1.1
20 270.9 -1.6
Table 4. Difference in percentage of dose received by 95% of PTV
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Madani et al. [28] compared 6 MV and 18 
MV photon intensity-modulated radiother-
apy (IMRT) for non-small cell lung cancer. 
Doses for a cohort of 10 patients, typical for 
our department, were computed with a com-
mercially available convolution/superposition 
(CS) algorithm. Final dose computation was 
also performed with a dedicated IMRT Monte 
Carlo dose engine (MCDE). CS plans showed 
higher D95% (Gy) for the GTV (68.13 vs 67.36, 
p = 0.004) and CTV (67.23 vs 66.87, p = 0.028) 
with 18 than with 6 MV photons. MCDE com-
putations demonstrated higher doses with 6 
MV than 18 MV in D95% for the PTV (64.62 vs 
63.64, p = 0.009), PTVoptim (65.48 vs 64.83, 
p = 0.014) and CTV (66.22 vs 65.64, p = 0.027). 
Dose inhomogeneity was lower with 18 than 
with 6 MV photons for GTV (0.08 vs 0.09, p 
= 0.007) and CTV (0.10 vs 0.11, p = 0.045) in 
CS but not MCDE plans. 6 MV photons signifi -
cantly (D33%; p = 0.045) spared the oesopha-
gus in MCDE plans. Observed dose differences 
between lower and higher energy IMRT plans 
were dependent on the individual patient. Se-
lection of photon energy depends on priority 
ranking of endpoints and individual patients. 
In the absence of highly accurate dose compu-
tation algorithms such as CS and MCDE, 6 MV 
photons may be the prudent choice.
Many lung cancer patients who undergo ra-
diation therapy are treated with higher energy 
photons (15–18 MV) to obtain deeper penetra-
tion and better dose uniformity. However, the 
longer range of the higher energy recoil elec-
trons in the low density medium may cause lat-
eral electronic disequilibrium and degrade the 
target coverage. To compare the dose homo-
geneity achieved with lower versus higher en-
Patient 
number
Bladder
(cc)
Bladder dosimetry data
Mean dose 
(Gy)
Volume in cc 
receiving >65Gy
Volume in % 
receiving >65Gy
6 MV 10 MV 6 MV 10 MV 6 MV 10 MV
1 89.86 46.21 47.1 18.30 21.36 20.36 23.77
2 99.18 62.62 64.47 54.18 60.71 54.63 61.21
3 99.92 46.93 44.53 20.76 17.99 20.78 18.00
4 110.39 37.92 40.03 19.53 18.49 17.69 16.75
5 112.16 49.8 49.84 29.68 34.39 26.46 30.66
6 118.99 44.06 42.42 20.47 17.69 17.2 14.87
7 125.11 40.6 39.12 19.57 16.59 16.26 15.77
8 127.35 42.89 40.26 19.20 18.54 15.08 14.56
9 161.10 35.06 28.64 20.90 21.80 14.53 13.53
10 170.63 50.2 43.25 52.84 32.06 30.97 18.79
11 223.49 37.99 38.31 17.92 20.85 8.02 9.33
12 240.99 38.97 39.24 40.53 40.46 16.82 16.79
13 252.56 28.11 28.5 27.60 31.01 10.93 12.28
14 261.16 28.85 28.83 31.86 30.56 12.2 11.70
15 323.58 34.35 24.49 42.13 50.35 13.02 15.56
16 333.61 21.33 32.19 42.60 46.04 12.77 13.8
17 374.22 34.24 35.85 52.35 55.16 13.99 14.74
18 380.07 19.66 19.20 31.81 28.51 8.37 7.50
19 381.94 2.53 2.17 30.12 31.10 10.66 11.52
20 441.92 19.33 19.77 29.52 28.06 6.68 6.35
Table 5. Bladder dosimetry data
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Patient 
number
Bladder
(cc)
Bladder dosimetry data
17% of bladder receiving dose 15% of bladder receiving dose
6 MV 10 MV 6 MV 10 MV
Gy % Gy % Gy % Gy %
1 89.86 67.02 80.39 68.13 81.72 68.54 82.2 69.24 83.05
2 99.18 76.22 91.42 77.82 93.34 76.44 91.69 78.05 93.62
3 99.92 66.72 80.03 65.71 78.8 67.84 81.37 67.03 80.4
4 110.39 66.18 79.38 64.69 77.6 69.94 83.53 67.34 80.78
5 112.16 71.15 85.34 72.36 86.79 72.54 87.01 73.37 88.01
6 118.99 65.4 78.46 62.01 74.38 68.07 81.65 64.85 77.78
7 125.11 62.09 71.26 63.1 70.96 65.66 80.65 64.98 79.78
8 127.35 61.08 73.26 60.68 72.78 69.56 83.44 64.06 76.84
9 161.1 37.46 69.66 38.49 71.36 37.64 74.62 38.54 75.02
10 170.63 72.62 87.11 65.76 78.88 73.12 87.71 66.56 79.89
11 223.49 56.31 67.54 55.07 66.06 59.06 70.85 57.9 69.46
12 240.99 64.49 77.35 64.51 78.15 67.88 81.42 67.19 81.4
13 252.56 56.9 68.3 59.16 70.96 60.37 72.41 61.36 73.61
14 261.16 58.61 67.76 55.17 66.77 58.61 70.3 58.95 70.72
15 323.58 55.93 64.93 62.51 74.99 60.11 69.79 65.81 78.94
16 333.61 56.2 67.42 62.5 57.1 59.9 71.86 64.2 61.36
17 374.22 61.3 73.52 62.52 74.99 63.84 76.57 64.74 77.66
18 380.07 44.81 53.75 42.71 51.23 50.2 60.6 47.43 56.8
19 381.94 46.65 55.75 47.12 52.73 49.63 54.25 48.69 55.23
20 441.92 39.94 47.91 41.31 49.55 44.4 53.23 44.51 53.39
Table 6. Bladder doses in Gy and percentage for 17% and 15% of volumes
ergy photon beams, Wang et al. [29] performed 
a dosimetric study of 6 and 15 MV three di-
mensional (3D) conformal treatment plans for 
lung cancer using an accurate, patient-specif-
ic dose-calculation method based on a Monte 
Carlo technique. A 6 and 15 MV 3D conformal 
treatment plan was generated for each of two 
patients with target volumes exceeding 200 
cm3 in an in-house treatment planning system 
in routine clinical use. Each plan employed 
four conformally shaped photon beams. Each 
dose distribution was recalculated with the 
Monte Carlo method, utilizing the same beam 
geometry and patient-specifi c computed to-
mography (CT) images. Treatment plans us-
ing the two energies were compared in terms 
of their isodose distributions and dose-volume 
histograms (DVHs). The 15 MV dose distribu-
tions and DVHs generated by the clinical treat-
ment planning calculations were as good as, or 
slightly better than, those generated for 6 MV 
beams. However, the Monte Carlo dose calcula-
tion predicted increased penumbra width with 
increased photon energy resulting in decreased 
lateral dose homogeneity for the 15 MV plans. 
Monte Carlo calculations showed that all target 
coverage indicators were signifi cantly worse 
for 15 MV than for 6 MV; in particular, the por-
tion of the planning target volume (PTV) re-
ceiving at least 95% of the prescription dose (= 
V95) dropped dramatically for the 15 MV plan 
in comparison to the 6 MV. Spinal cord and 
lung doses were clinically equivalent for the 
two energies. In treatment planning of tumours 
that abut lung tissue, lower energy (6 MV) pho-
ton beams should be preferred over higher en-
ergies (15–18 MV) because of the signifi cant 
loss of lateral dose equilibrium for high-energy 
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Patient 
number
Rectum
(cc)
Rectum dosimetry data
Mean dose 
(Gy)
Volume in cc 
receiving >65Gy
Volume in % 
receiving >65Gy
6 MV 10 MV 6 MV 10 MV 6 MV 10 MV
1 34.17 52.84 52.84 10.19 10.86 29.81 31.78
2 38.09 8.87 10.33 7.93 7.62 20.82 20.00
3 47.43 46.94 43.69 12.64 13.08 26.64 27.58
4 60.97 48.28 43.78 14.63 16.30 24.00 26.74
5 61.32 35.61 36.61 11.76 10.85 19.18 17.69
6 69.85 55.88 54.04 15.24 15.82 21.82 22.65
7 70.26 12.57 12.26 11.33 11.40 16.12 16.22
8 71.13 46.63 44.86 18.33 18.15 25.77 25.51
9 71.35 54.04 55.07 24.83 25.14 34.80 35.23
10 71.89 35.8 33.1 10.68 12.59 14.85 17.51
11 77.65 43.56 43.88 15.45 19.85 19.90 25.56
12 78.37 46.08 44.41 23.93 25.08 30.54 32.00
13 79.83 52.94 54.31 28.50 28.28 35.70 35.43
14 80.99 47.31 49.08 21.89 21.87 27.03 27.00
15 86.72 51.44 53.4 24.97 26.02 28.79 30.00
16 95.24 42.37 43.11 22.67 21.11 23.80 22.17
17 121.32 32.87 35.34 15.14 17.74 12.48 14.62
18 124.53 37.79 38.04 29.89 27.99 24.00 22.48
19 129.3 36.06 33.48 32.69 33.88 25.28 26.20
20 267.18 27.56 26.35 33.66 36.42 12.60 13.63
Table 7. Rectum dosimetry data
beams in the low-density medium. Any gains 
in radial dose uniformity across steep den-
sity gradients for higher energy beams must 
be weighed carefully against the lateral beam 
degradation due to penumbra widening.
Aoyama et al. [30] designed a study to eval-
uate the integral dose (ID) received by normal 
tissue from intensity-modulated radiotherapy 
(IMRT) for prostate cancer. Twenty-fi ve ra-
diation treatment plans including IMRT using 
a conventional linac with both 6 MV (6MV-
IMRT) and 20 MV (20MV-IMRT), as well as 
three-dimensional conformal radiotherapy 
(3DCRT) using 6 MV (6MV-3DCRT) and 
20 MV (20MV-3DCRT) and IMRT using Tomo-
Therapy (6MV) (Tomo-IMRT), were created 
for 5 patients with localized prostate cancer. 
The ID (mean dose _ tissue volume) received 
by normal tissue (NTID) was calculated from 
dose–volume histograms. The 6MV-IMRT re-
sulted in 5.0% lower NTID than 6MV-3DCRT; 
20 MV beam plans resulted in 7.7%–11.2% 
lower NTID than 6MV-3DCRT. Tomo-IMRT 
NTID was comparable to 6MV-IMRT. Com-
pared with 6MV-3DCRT, 6MV-IMRT reduced 
IDs to the rectal wall and penile bulb by 6.1% 
and 2.7%, respectively. Tomo-IMRT further 
reduced these IDs by 11.9% and 16.5%, re-
spectively. The 20 MV plan did not reduce IDs 
to those structures. The difference in NTID 
between 3DCRT and IMRT is small. The 20 
MV plans somewhat reduced NTID compared 
with 6 MV plans. The advantage of TomoTher-
apy over conventional IMRT and 3DCRT for 
localized prostate cancer was demonstrated 
in regard to dose sparing of rectal wall and 
penile bulb while slightly decreasing NTID as 
compared with 6MV-3DCRT.
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Patient 
number
Rectum
(cc)
Rectum dosimetry data
17% of rectum receiving dose 15% of rectum receiving dose
6 MV 10 MV 6 MV 10 MV
Gy % Gy % Gy % Gy %
1 34.17 71.3 85.53 72.15 87.41 72.46 86.92 73.23 88.72
2 38.09 67.04 80.9 69.03 82.8 68.97 81.4 70.66 83.6
3 47.43 72.49 86.95 71.79 86.12 73.54 88.21 72.38 87.3
4 60.97 71.64 85.93 71.26 85.47 72.63 87.12 72.73 87.24
5 61.32 65.58 78.66 63.23 80.64 67.43 80.89 69.1 82.89
6 69.85 70.58 85.06 70.85 84.2 72.06 86.83 71.34 84.87
7 70.26 69.2 71.88 69.9 71.51 69.8 70.99 69.99 72.02
8 71.13 71.9 86.3 70.95 85.1 73.11 87.7 71.93 86.28
9 71.35 72.58 87.06 71.85 86.19 74.06 88.83 72.34 86.77
10 71.89 65.88 79.02 61.96 74.32 68.73 82.44 64.82 77.75
11 77.65 70.48 84.54 67.34 80.77 70.97 85.13 69.11 82.89
12 78.37 76.28 91.5 74.91 89.85 77.11 92.5 75.77 90.89
13 79.83 73.8 85.64 74.89 89.84 74.42 86.41 75.69 90.79
14 80.99 70.12 65.66 70.99 68.67 70.22 65.39 70.89 70.63
15 86.72 67.06 81.46 71.48 85.74 69.02 82.79 73.08 87.66
16 95.24 71.37 85.6 70.3 84.32 73.6 88.29 71.78 86.1
17 121.32 62.71 75.22 61.2 73.4 64.66 77.56 62.74 75.26
18 124.53 68.27 81.89 70.4 84.45 70.64 84.73 72.06 86.43
19 129.3 76.1 91.28 69.82 83.74 76.8 92.12 70.68 84.78
20 267.18 62.75 75.27 60.05 72.04 64.67 77.6 62.26 74.68
Table 8. Rectum doses in Gy and percentage for 17% and 15% of volumes
The dose delivered to patients by photons 
and neutrons outside the radiation fi elds when 
beam intensity modulation conformal radio-
therapy is given is estimated. These estimates 
are then used to compute the risk of secondary 
cancers as a sequela of the radiation therapy. 
The x-ray and neutron leakage accompanying 
two beam intensity modulation techniques de-
livered by currently available linear accelera-
tors was estimated by Followill et al. [31] for 
6 MV, 18 MV and 25 MV x-ray energies. Es-
timates of whole body dose equivalents were 
determined using leakage measurements re-
ported in the literature and treatment param-
eters derived for two modulated beam intensi-
ty conformal therapy techniques. Risk values 
recommended by the National Council on Ra-
diation Protection and Measurements (NCRP) 
were used to estimate the resulting risk of fa-
tal radiation induced cancer for 70.00 Gy pre-
scribed tumour dose. The computed worst case 
risks of secondary cancers increased in the 
range from 1.00% for 6 MV x-rays to 24.4% for 
25 MV x-rays. Careful consideration should be 
made of the risks associated with secondary 
whole body radiation before implementation of 
beam intensity-modulated conformal therapy 
at x-ray energies greater than 10 MV.  
Howell et al. [32] calculated effective dos-
es from the delivery of 6 MV, 15 MV, and 18 
MV conventional and intensity-modulated ra-
diation therapy (IMRT) prostate treatment 
plans. ICRP-60 tissue weighting factors were 
used for the calculations. Photon doses were 
measured in a phantom for all beam energies. 
Neutron spectra were measured for 15 MV and 
18 MV and ICRP-74 quality conversion factors 
used to calculate ambient dose equivalents. 
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Patient 
number
6 MV photons
cc-Gy
10 MV photons
cc-Gy
% Difference
1 159989.48 151341.40 -5.4
2 138753.20 135832.08 -2.1
3 133354.80 117883.90 -11.6
4 198935.02 194702.36 -2.1
5 241913.70 228639.60 -5.5
6 108752.73 108473.16 -0.3
7 124763.16 120816.88 -3.2
8 134033.285 129453.56 -3.4
9 142978.22 136364.69 -4.6
10 135379.29 135708.68 0.2
11 125606.28 124896.64 -0.6
12 173798.72 164494.72 -5.4
13 159454.72 159855.36 0.3
14 122377.1 123221.08 0.7
15 62439.96 58182.69 -6.8
16 192734.75 174083.00 -9.7
17 205308.35 194100.45 -5.5
18 167917.7 162501.00 -3.2
19 174800.87 165255.43 -5.5
20 253894.93 235271.83 -7.3
Table 9. Normal tissue integral doses
Patient 
number
6 MV 
photons
10 MV 
photons
1 0.885 0.955
2 0.687 0.804
3 0.863 0.826
4 0.953 0.853
5 0.847 0.764
6 0.745 0.922
7 0.781 0.814
8 0.774 0.856
9 0.887 0.796
10 0.815 0.854
11 0.811 0.886
12 0.853 0.939
13 0.867 0.832
14 0.844 0.885
15 0.812 0.855
16 0.937 0.917
17 0.887 0.872
18 0.844 0.745
19 0.884 0.814
20 0.965 0.955
Table 10. Conformity indices for 6 MV and 10 MV photon beams
The ambient dose equivalents were corrected 
for each tissue using neutron depth dose data 
from the literature. The depth-corrected neu-
tron doses were then used as a measure of 
the neutron component of the ICRP protec-
tion quantity, organ equivalent dose. IMRT 
resulted in an increased photon dose to many 
organs. However, the IMRT treatments re-
sulted in an overall decrease in effective dose 
compared to conventional radiotherapy. This 
decrease correlates with the ability of an in-
tensity-modulated fi eld to minimize the dose 
to critical normal structures in close proxim-
ity to the treatment volume. In a comparison 
of the three beam energies used for the IMRT 
treatments, 6 MV resulted in the lowest effec-
tive dose, while 18 MV resulted in the highest 
effective dose. This is attributed to the large 
neutron contribution for 18 MV compared to 
no neutron contribution for 6 MV.
We evaluated a cohort of 20 prostate 
cancer patients wherein the PTV ranged 
from 38.91 cc to 270.91 cc (roughly a ra-
tio of 7.0). Except for energy all the treat-
ment planning parameters were the same 
for these patients. Percentage of doses re-
ceived by % of PTV was higher for 6 MV 
photons compared to 10 MV photons for 12 
patients. Percentage doses received by 15% 
of bladder volume were higher for 10 MV 
photons. Percentage doses received by 15% 
of rectum volume were also higher for 10 
MV photons. 
Normal tissue integral doses for the twenty 
patients were higher for 6 MV photons compared 
to 10 MV photons, though by a small percentage. 
There was no particular advantage seen for 10 
MV photons in terms of conformity index values. 
Since 10 MV photons lie on the threshold energy 
border for the induction of photoneutrons from 
the accelerator components, we recommend 
the use of 6 MV photons for IMRT of prostate 
cancer to achieve higher tumour control and ac-
ceptable complication rate.
01_03.indd   29 2009-11-13   11:11
30 REP PRACT ONCOL RADIOTHER • 2009 • 14/1/: 18–31
ORIGINAL PAPER
Acknowledgement:
We thank Dr. Munther Alqaisi MD, Medical 
Director, Mojave Radiation Oncology, Apple 
Valley, CA, USA for his continued help and 
support to complete this work.    
REFERENCES
1.  Laughlin JS, Mohan R, Kutcher GJ: Choice of op-
timum megavoltage for accelerators for photon 
beam treatment. Int J Radiat Oncol Biol Phys, 
1986; 12: 1551–7
2.  Garrison H, Anderson J, Laughlin JS, et al: Com-
parison of dose distributions in patients treated 
with X-ray beams of widely different energies. 
Radiology, 1952; 58: 361–8
3.  Sternick ES, Bleier AR, Carol MP, et al: Intensity 
modulated radiation therapy: What photon en-
ergy is best? (Abstr.). Proceedings of the Inter-
national Conference on the Use of Computers in 
Radiation Therapy (ICCR), XIIth Annual Meet-
ing, Salt Lake City, UT. Madison, WI: Medical 
Physics Publishing; 1997; 418–19
4.  Soderstrom S, Eklof A, Brahme A: Aspects on 
the optimal photon beam energy for radiation 
therapy. Acta Oncol, 1999; 38: 179–87
5.  Adams EJ, Convery DJ, Cosgrove VP et al: Clini-
cal implementation of dynamic and step-and-
shoot IMRT to treat prostate cancer with high 
risk of pelvic lymph node involvement. Radio-
ther Oncol, 2004; 70(1): 1–10
6.  Bos LJ, Schwarz M, Bar W et al: Comparison be-
tween manual and automatic segment generation 
in step-and shoot IMRT of prostate cancer. Med 
Phys, 2004; 31(1): 122–30
7.  Burman C, Chui CS, Kutcher G et al: Planning, 
delivery, and quality assurance of intensity-mod-
ulated radiotherapy using dynamic multileaf 
collimator: a strategy for large-scale implemen-
tation for the treatment of carcinoma of the pros-
tate. Int J Radiat Oncol Biol Phys, 1997; 39(4): 
863–73
8.  Cheung P, Sixel K, Morton G et al: Individualized 
planning target volumes for intrafraction motion 
during hypofractionated intensity-modulated ra-
diotherapy boost for prostate cancer. Int J Radiat 
Oncol Biol Phys, 2005; 62(2): 418–25
9.  Corletto D, Iori M, Paiusco M et al: Inverse and 
forward optimization of one- and two-dimension-
al intensity modulated radiation therapy-based 
treatment of concave-shaped planning target 
volumes: the case of prostate cancer. Radiother 
Oncol, 2003; 66(2): 185–95
10.  De Meerleer G, Vakaet L, Meersschout S et al: 
Intensity-modulated radiotherapy as primary 
treatment for prostate cancer: acute toxicity in 
114 patients. Int J Radiat Oncol Biol Phys, 2004; 
60(3): 777–87
11. Debus J, Zierhut D, Didinger B, Schlegel W, Wan-
nenmacher M: Inverse planning and intensity-
modulated radiotherapy in patients with prostate 
cancer. Front Radiat Ther Oncol, 2002; 36: 25–34
12.  Fraass BA, Kessler ML, McShan DL, et al: Opti-
mization and clinical use of multisegment inten-
sity-modulated radiation therapy for high-dose 
conformal therapy. Semin Radiat Oncol, 1999; 
9(1): 60–77
13.  Leibel SA, Fuks Z, Zelefsky MJ, et al: Technolog-
ical advances in external-beam radiation therapy 
for the treatment of localized prostate cancer. 
Semin Oncol, 2003; 30(5): 596–615
14.  Ma L, Yu CX, Earl M, et al: Optimized intensity-
modulated arc therapy for prostate cancer treat-
ment. Int J Cancer, 2001; 96(6): 379–84
15.  Martinez AA, Yan D, Lockman D et al: Im-
provement in dose escalation using the process 
of adaptive radiotherapy combined with three-
dimensional conformal or intensity-modulated 
beams for prostate cancer. Int J Radiat Oncol 
Biol Phys, 2001; 50(5): 1226–34
16.  Pollack A, Hanlon A, Horwitz EM, Feigenberg 
S, Uzzo RG, Price RA: Radiation therapy dose 
escalation for prostate cancer: a rationale for 
IMRT. World J Urol 2003; 21(4): 200–8
17.  Price RA, Murphy S, McNeeley SW et al: A 
method for increased dose conformity and seg-
ment reduction for SMLC delivered IMRT treat-
ment of the prostate. Int J Radiat Oncol Biol 
Phys, 2003; 57(3): 843–52
18.  Teh BS, Woo SY, Mai WY et al: Clinical experi-
ence with intensity-modulated radiation therapy 
(IMRT) for prostate cancer with the use of rectal 
balloon for prostate immobilization. Med Dosim, 
2002; 27(2): 105–13
19.  Zelefsky MJ, Fuks Z, Happersett L et al: Clinical 
experience with intensity modulated radiation 
therapy (IMRT) in prostate cancer. Radiother 
Oncol, 2000; 55(3): 241–9
20. Pirzkall A, Carol MP, Pickett B, Xia P, Roach 
M 3rd, Verhey LJ: The effect of beam energy 
and number of fi elds on photon-based IMRT 
for deep-seated targets. Int J Radiat Oncol Biol 
Phys, 2002; 53(2): 434–42
21.  Sternick ES, Bleier AR, Carol MP: Intensity 
modulated radiation therapy: what photon en-
01_03.indd   30 2009-11-13   11:11
Solaiappan G et al • Infl uence of photon beam energy on IMRT
31REP PRACT ONCOL RADIOTHER • 2009 • 14/1/: 18–31
ergy is best? Presentation at The XIIth Inter-
national Conference on the Use of Computers in 
Radiation Therapy (ICCR); Salt Lake City, UT; 
27–30 May 1997
22.  Howell RM, Ferenci MS, Hertel NE, Fullerton 
GD: Investigation of secondary neutron dose for 
18 MV dynamic MLC IMRT delivery. Med Phys, 
2005; 32(3): 786–93
23.  Kry SF, Salehpour M, Followill DS et al: Out-of-
fi eld photon and neutron dose equivalents from 
step-and-shoot intensity-modulated radiation 
therapy. Int J Radiat Oncol Biol Phys, 2005; 
62(4): 1204–16
24.  Waller EJ: Neutron production associated with 
radiotherapy linear accelerators using intensity 
modulated radiation therapy mode. Health Phys, 
2003; 85(5 suppl): S75–S77
25.  Sun M, Ma L: Treatment of exceptionally large 
prostate cancer patients with low-energy inten-
sity-modulated photons. Jr Appl Clin Med Phys, 
2006; 7: 43–9 
26.  Boer SFD, Kumek Y, Jaggernauth W, Podgorsak 
MB: The effect of beam energy on the quality of 
IMRT plans for prostate conformal radiotherapy. 
Tech Can Res Treat, 2007; 6: 139–46
27. Weiss E, Siebers JV, Keall PJ: An analysis of 
6-MV versus 18-MV photon energy plans for in-
tensity modulated radiation therapy (IMRT) of 
lung cancer. Radiother Oncol, 2007; 82: 55–62
28. Madani I, Vanderstraeten B, Bral S, et al: Com-
parison of 6 MV and 18 MV photons for IMRT 
treatment of lung cancer. Radiother Oncol, 2007; 
82: 63–9
29. Wang L, Yorke E, Desobry G, Chui CS: Dosim-
etric advantage of using 6 MV over 15 MV pho-
tons in conformal therapy of lung cancer: Monte 
Carlo studies in patient geometries. J Appl Clin 
Med Phys, 2002; 3: 51–9
30. Aoyama H, Westerley DC, Mackie TR et al: In-
tegral radiation dose to normal structures with 
conformal external beam radiation. Int J Radiat 
Oncol Biol Phys, 2006; 64: 962–7
31. Followill D, Geis P, Boyer A: Estimates of whole 
body dose equivalent produced by beam inten-
sity modulated conformal therapy. Int J Radiat 
Oncol Biol Phys, 1997; 38: 667–72
32. Howell RM, Hertel NE, Wang Z, et al: Calcu-
lation of effective dose from measurements of 
secondary neutron spectra and scattered photon 
dose from dynamic MLC IMRT for 6 MV, 15 MV 
and 18 MV energies. Med Phys 2006; 33: 360–8
01_03.indd   31 2009-11-13   11:11
